Clinical development failure
Lead assets must prove efficacy and safety in pivotal and follow-on studies before approval.
- Scope
- Apitegromab, SRK-439, and other pipeline programs
- Materiality
- high
Scholar Rock Holding Corp
Scholar Rock Holding Corp is a U.S.-based biotechnology company focused on discovering and developing medicines that modulate growth factor signaling for severe diseases. Its lead programs center on apitegromab and other anti-myostatin candidates for neuromuscular disorders, with development, manufacturing, and future commercialization activities organized through third-party partners and internal research capabilities.
6.95
6.95
| % | |
|---|---|
| Lead therapeutic candidate | 0% Apitegromab and related clinical-stage development for SMA and adjacent neuromuscular uses. |
| Pipeline biologics | 0% Anti-myostatin and other antibody-based programs under preclinical and clinical development. |
| Discovery platform | 0% Proprietary antibody discovery and optimization capabilities used to generate new candidates. |
| Development and regulatory activities | 0% Clinical trial execution, regulatory filings, and supporting development work for product candidates. |
Scholar Rock’s direct end customers, if its products are approved, are patients with rare neuromuscular diseases and...
- SMA patients and treating physiciansprimary
They would use apitegromab if approved to treat spinal muscular atrophy and related neuromuscular conditions.
- Rare disease payors and market access stakeholdersprimary
They determine coverage, reimbursement, and formulary access for high-cost specialty biologics.
- Specialty neuromuscular clinicssecondary
They diagnose, monitor, and administer therapies for patients in the target disease areas.
- Research and manufacturing partnerssecondary
They provide discovery, clinical manufacturing, and development services under outsourced arrangements.
Scholar Rock is headquartered in the United States and develops therapies for global markets, with commercialization...
- •Headquartered in the United States
- •Primary development and regulatory activity in the U.S.
- •European commercialization planning includes Germany
- •Global launch intent for approved products
- •Outsourced manufacturing and vendors add cross-border execution risk
The company’s strategy is to advance apitegromab through regulatory approval and build the commercial infrastructure...
01
Regulatory advancement of apitegromabshort-term
Approval is the key value-creation step and the basis for first product revenue.
02
Commercial build-outshort-term
The company needs sales, market access, medical affairs, and distribution capabilities to launch.
03
Pipeline expansionmedium-term
A broader portfolio reduces dependence on a single lead asset and extends the platform.
Scholar Rock faces the classic biotech risk stack: clinical failure, regulatory delay, and uncertainty around eventual...
Regulatory delay or rejection
FDA and EMA decisions determine whether the company can commercialize its lead product.
- Scope
- BLA/MAA review and post-review requirements
- Materiality
- high
Commercialization execution risk
The company has limited sales and distribution experience and must build capabilities or partner.
- Scope
- U.S. and European launch readiness
- Materiality
- high
Reimbursement and pricing pressure
Specialty biologics depend on third-party payor coverage and favorable access terms.
- Scope
- Rare disease market access
- Materiality
- high
Manufacturing and supply chain dependence
All clinical manufacturing is outsourced, increasing reliance on third-party capacity and quality.
- Scope
- Clinical supply and future commercial supply
- Materiality
- medium
Research and development expense recognition
Affects operating loss and comparability across periods
Stock-based compensation
Can materially affect reported operating expense
Capitalization and liquidity assumptions
Important for going-concern and financing analysis
Collaboration and license accounting
Could affect revenue or other income recognition
: 29.4.2026